Universal CAR-T cells for acute myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a type of immunotherapy called CAR-T cells that are made to target leukemia cells. The cells are designed to attack AML by recognizing several proteins on the cancer cells, and may be an option for patients who have not responded well to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be older than 6 months.
- Your leukemia cells must have at least one of these proteins: CLL-1, CD123, CD38, or CD33.
- You should be up and doing most of your daily activities (KPS score more than 80) and expected to live longer than 3 months.
- Your heart, lungs, liver, and kidneys must be working well enough based on blood and other tests.
- You must not have an active infection that is not under control, or HIV or hepatitis C.
- You must not be pregnant or nursing, and cannot have had prior gene therapy or systemic steroids within the last week.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a lab-made immune cell treatment (CAR T cells) that targets specific markers on acute myeloid leukemia cells. It aims to control the leukemia, but it also involves close monitoring because it is an early-phase study.
This trial tests a new treatment called universal CLL1 CAR-T cells for people whose acute myeloid leukemia (AML) has come back or hasn't responded to standard treatments. It aims to see if these specially designed immune cells can find and attack leukemia cells that carry a marker called CLL1.
This study tests a new kind of immunotherapy called CAR-T cells that are engineered to find and attack leukemia cells carrying certain markers (CD33, CD123, or CLL-1). The treatment is given in two steps, aiming to kill cancer cells more effectively and possibly with fewer side effects.
This study tests a new CAR-T cell therapy that targets two proteins, CLL1 and CD38, on leukemia cells. It is designed for people whose acute myeloid leukemia has returned or not responded to treatment.
This trial tests a lab-made immune cell treatment (CAR-T) made to target AML cells with a specific marker (NKG2D ligand). It’s for people whose acute myeloid leukemia (AML) has come back or didn’t respond to standard chemotherapy.
This early-phase study tests a customized immune-cell therapy (CAR-T) made from your own T cells to treat acute myeloid leukemia (AML) that has the marker CD123. It may help shrink the leukemia and improve long-term control, but the treatment is still being tested for safety and early effectiveness.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.